Tinzaparin as an antithrombotic: An overview

Hospital Medicine

Volumn 59, Issue 2, 1998, Pages 145-148

  Fegan, C D ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ARTICLE; HUMAN; LUNG EMBOLISM; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOPHLEBITIS;

FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; PULMONARY EMBOLISM; THROMBOPHLEBITIS;

EID: 0031993372     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Anon (1986) Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 256: 744-9
2. Akiba T, Tachibana K, Ozawa K et al (1992) Long term use of low molecular weight heparin ameliorates hyperlipidaemia in patients on hemodialysis. Asaio J 38: M326-30
3. Friedel H, Balfour J (1994) Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 48: 638-60
4. Green D, Lee M, Lim A et al (1990) Prevention of thromboembolism after spinal cord injury using low molecular weight heparin. Ann Intern Med 113: 571-4
5. Hirsh J, Levine M (1992) Low molecular weight heparin. Blood 79: 1-17
6. Hull R, Raskob G, Pineo G et al (1992) Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 326: 975-82
7. Hull R, Raskob G, Pineo G et al (1993) A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 329: 1370-6
8. Lassen M, Morris L, Christiansen H et al (1991) Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthopaed Scand 62: 33-8
9. Leizorovicz A, Bara L, Samama M, Haugh M (1993) Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasia 23 (Suppl 1): 89-98
10. Matzsch T, Bergqvist D, Fredin H et al (1990) Low molecular weight heparin compared with dextran and prophylaxis against thrombosis after total hip replacement. Acta Chirurg Scand 156: 445-50
11. Matzsch T, Bergqvist D, Fredin H et al (1991) Comparison of the thromboprophylactic effect of a low molecular weight heparin vs dextran in total hip replacement. Thromb Haemorrhagic Disord 3: 25-9
12. Ryan K, Lane D, Flynn J, Shepherd J, Ireland H, Curtis JR (1991) Dose finding study of a low molecular weight heparin, innohep in haemodialysis. Thromb Haemost 66: 277-82
13. Shaughnessy S, Young E, Deschamps P, Hirsch J (1995) The effect of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86: 1368-73
14. Simonneau G, Sors H, Charbonnier B et al (1997) A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 337: 663-9
15. Simpson H, Baird J, Allison M et al (1996) Long term use of the low molecular weight heparin tinzaparin in haemodialysis. Haemostasis 26: 90-7
16. Siragusa S, Cosmi B, Barone M, Beltrametti C, Serafini S, Piovella F (1997) Low molecular weight heparins: are different preparations comparable in the treatment of venous thromboembolism. Blood 90 (Suppl 1): 3264
17. Valette F, Hoffmeyer V, Lloyd A (1995) Economic evaluation of the use of tinzaparin in the treatment of deep vein thrombosis. Br J Med Econ 8: 111-23
18. Verstraete M (1993) The diagnosis and treatment of deep vein thrombosis. N Engl J Med 329: 1418-20